Personal information

No personal information available

Activities

Collapse all

Employment (1)

Universitair Medisch Centrum Groningen: Groningen, Groningen, NL

(Dept. of Gastroenterology and Hepatology)
Employment
Source: Self-asserted source
Amber Bangma

Education and qualifications (1)

Rijksuniversiteit Groningen: Groningen, Groningen, NL

2015-09 to 2018-08 | BSc Medicine
Education
Source: Self-asserted source
Amber Bangma

Works (7)

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

Gut Microbes
2024-12-31 | Journal article
DOI: 10.1080/19490976.2024.2391505
Contributors: Femke M. Prins; Iwan J. Hidding; Marjolein A.Y. Klaassen; Valerie Collij; Johannes P.D. Schultheiss; Werna T.C. Uniken Venema; Amber Bangma; Jurne B. Aardema; Bernadien H. Jansen; Wout G.N. Mares et al.
Source: check_circle
Crossref

Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis

2024-07-23 | Preprint
DOI: 10.1101/2024.07.23.24310848
Contributors: Amber Bangma; Paola Pibiri; Shiqiang Sun; Sofie De Jong; Emilia Bigaeva; Johannes R. Björk; Naomi Karmi; Gwenny M.P.J. Verstappen; Frans G.M. Kroese; Gursah Kats-Ugurlu et al.
Source: check_circle
Crossref

Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease

Nature Communications
2024-02-17 | Journal article
DOI: 10.1038/s41467-024-45855-2
Contributors: Shixian Hu; Arno R. Bourgonje; Ranko Gacesa; Bernadien H. Jansen; Johannes R. Björk; Amber Bangma; Iwan J. Hidding; Hendrik M. van Dullemen; Marijn C. Visschedijk; Klaas Nico Faber et al.
Source: check_circle
Crossref

High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis

2023-10-02 | Preprint
DOI: 10.21203/rs.3.rs-3348629/v1
Contributors: Eleonora Festen; Shiqiang Sun; Paola Pibiri; Naomi Karmi; Roy Oelen; Sofie de Jong; Amber Bangma; Johan Teunis; Gursah Kats-Ugurlu; Maria Paraskevopoulou et al.
Source: check_circle
Crossref

Mucosal host–microbe interactions associate with clinical phenotypes in inflammatory bowel disease

2022-06-04 | Preprint
DOI: 10.1101/2022.06.04.494807
Contributors: Shixian Hu; Arno R. Bourgonje; Ranko Gacesa; Bernadien H. Jansen; Johannes R. Björk; Amber Bangma; Iwan J. Hidding; Hendrik M. van Dullemen; Marijn C. Visschedijk; Klaas Nico Faber et al.
Source: check_circle
Crossref

Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease

PLOS ONE
2021-09-17 | Journal article
DOI: 10.1371/journal.pone.0256860
Contributors: Naomi Karmi; Cinzia Ciccacci; Amber Bangma; Lieke M. Spekhorst; Hendrik M. van Dullemen; Marijn C. Visschedijk; Gerard Dijkstra; Rinse K. Weersma; Michiel D. Voskuil; Eleonora A. M. Festen
Source: check_circle
Crossref

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease

Alimentary Pharmacology & Therapeutics
2020-06 | Journal article
DOI: 10.1111/apt.15762
Contributors: Amber Bangma; Michiel D. Voskuil; Werna T. C. Uniken Venema; Harm Brugge; Shixian Hu; Pauline Lanting; Lude Franke; Gerard Dijkstra; Eleonora A. M. Festen; Rinse K. Weersma
Source: check_circle
Crossref
How many people are using ORCID?